Canadian psychedelics company Nova Mentis Life Science Corp. NMLSF, or NOVA, works with that Toronto Institute of Pharmaceutical Technology (TIPT), a Health Canada licensed GMP manufacturing and testing facility to complete the production of a technical quantity of psilocybin microdose capsules.
The partners are moving forward with the release testing phase to generate data required for the Canadian application process Advancing a Phase IIa clinical trial of psilocybin microdose therapy for Fragile X Syndrome (FXS), the leading genetic cause of Autism Spectrum Disorder (ASD).
The Company has partnered with contract research organization KGK Science Inc. to develop its psilocybin drug portfolio by jointly submitting the Health Canada clinical trial application.
NOVA’s work focuses on the development of diagnostics and psilocybin-based therapeutics for neuroinflammatory diseases and debilitating chronic diseases.
The company received orphan drug status in both the United States and the European Union for the use of Psilocybin to treat FXS. After drug approval, NOVA manufactured a large amount of it >98% pure psilocybin for clinical trials and commercialization.
Current preclinical research showed that a very low microdose formulation of NOVA’s psilocybin compound NM-1001 significantly modulated behavioral and cognitive defects in a genetic model of FXS.
Photo of Robina Weermeijer on Unsplash
